**Table of Contents**

Quasi-Poisson Segmented Regression Model (pg. 2)

Table 1. Naloxone kits dispensed by Public Health Units and community-based organizations (pg. 3)

Data source references (pg. 4)

Table 2. Synthetic control predictor weights (pg. 7)

Table 3. Synthetic control donor public health units (pg. 8)

Table 4. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis (pg. 9)

Figure 1. Controlled interrupted time-series of opioid-related ED visits plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 12)

Figure 2. Controlled interrupted time-series of opioid-related hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 13)

Figure 3. Controlled interrupted time-series of opioid-related mortalities plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 14)

**Quasi-Poisson Segmented Regression Model**

We fitted quasi-Poisson generalized linear regression models with a log link to account for monthly event counts of zero in our data:

$$Outcome\_{jkt}= β\_{0}+β\_{1}time\_{t}+β\_{2}group\_{k}+β\_{3}time\_{t}group\_{k}+β\_{4}level\_{jt}+β\_{5}trend\_{jt}+β\_{6}level\_{jt}group\_{k}+β\_{7}trend\_{jt}group\_{k}+η'z\_{t}+ε\_{jkt} $$

where j was the intervention, t was the study time in monthly intervals pre- and post-intervention, and k distinguished between treated and synthetic control group. Significant values for exponentiated β2 and β3 terms indicated level and trend differences between the treated and synthetic control groups pre-intervention, respectively. Significant values for exponentiated β6 and β7 terms indicated level and trend differences, respectively, between treated and synthetic control groups post-implementation. The time varying confounders (booth-hours, persons receiving OAT, and naloxone kits dispensed per hundred units) are represented by the vector of measured covariates $η'z\_{t}$.

Table 1. Naloxone kits dispensed by Public Health Units and community-based organizations

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PHU | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Source |
| Algoma |  |  |  | 355 | 590 | 737 |  |  | 61-63 |
| Brant County |  |  |  | 172 | 428 | 1365 | 1282 | 4306§ | 64-66 |
| Chatham-Kent |  |  |  | 92 | 381 | 342 | 429 |  | 67-69 |
| Hamilton |  |  | 924 | 3402 | 6412 | 17705 | 16613 | 10486§ | 70,71 |
| Durham Region |  |  |  | 458 🡪 |  |  |  | 72 |
| Eastern Ontario |  |  |  | 13 🡪 |  |  |  | 72 |
| Grey-Bruce |  |  |  | 437 | 1337 |  |  | 2434§ | 73,74 |
| Haldimand-Norfolk |  |  |  | 0 | 352 |  |  |  | 72,75 |
| Haliburton |  |  |  | 297 | 802 |  |  | 72,76 |
| Halton Region |  |  |  | 226 🡪 | 223 | 320 | 343§ | 72,77 |
| Hastings Prince Edward County |  |  | 39 | 166 | 326 | 890 |  |  | 78,79 |
| Kingston  |  |  |  | 456 | 1419 |  |  |  | 80 |
| Lambton |  |  |  | 508 | 700 | 2015 |  |  | 72,81,82 |
| Leeds |  |  |  | 408 🡪 |  |  |  | 72 |
| London | 40 | 98 | 168 | 848 | 2381 | 5289 |  |  | 83 |
| Niagara |  |  |  | 1482 🡪 | 4761 | 5885 | 5296§ | 72 84 |
| North Bay |  |  |  | 500 | 2000 | 4000 |  |  | 85 |
| Northwestern |  |  |  | 825 | 816 |  |  |  | 86,87 |
| Ottawa |  |  | 115 | 1300 | 5500 |  |  |  | 88-90 |
| Peel |  |  |  | 366 | 1376 |  |  |  | 91 |
| Peterborough |  |  |  | 833 |  |  |  |  | 72 |
| Porcupine |  |  |  | 224 | 906 | 2656 |  |  | 92,93 |
| Renfrew |  |  |  | 53 | 197 | 233 |  |  | 94-96 |
| Simcoe Muskoka |  |  | 462 | 1700 | 1620 | 2595 |  |  | 71,97,98 |
| Sudbury |  |  |  | 1235 |  | 10010 | 15438\* | 21057§ | 72,99,100 |
| Thunder Bay | 34 | 32 | 35 | 554 | 2022 | 4216 | 6846 |  | 101 |
| Timiskaming |  |  |  | 18 🡪 |  |  |  | 72 |
| Toronto | 🡨 2000 |  | 7717 | 42294 | 51577 | 67012 |  | 1,102-104 |
| Waterloo |  |  | 677 | 4703 | 6782 |  |  |  | 105,106 |
| Guelph |  |  |  | 581 🡪 | 1419 |  |  |  | 72,107 |
| Windson-Essex |  |  |  | 1461 🡪 | 3059 | 5378 |  |  | 72,108 |
| York |  |  |  | 560 🡪 | 2380 |  |  | 72,109 |

\*Monthly counts available

§Most recent count

🡪 July 1 2017 – June 30 2018

🡨2011 – 2015, inclusive

**DATA SOURCE REFERENCES:**

1. Medical Officer of Health. Toronto Overdose Action Plan: Status Report 2018. in *Report for Action*, Vol. HL27.01 (City of Toronto, Toronto, ON, 2018).

2. CBC News. Toronto's first permanent supervised injection site opens downtown. in *CBC News* (Toronto, ON, 2017).

3. Surveillance & Epidemiology. Toronto Overdose Information System. (City of Toronto, Toronto, ON, 2021).

4. Draaisma, M. & Lucs, I. The Works superised injection site reopens with physical distancing measures in place. in *CBC News* (Toronto, ON, 2020).

5. Toronto Drop-In Network. Overdose Prevention Site, Supervised Injection Services and Safe Consumption Service Hours List. (Toronto, ON, 2018).

6. Harm Reduction TO. Supervised Consumption Services: OPS, SIS/SCS, & CTS. (24 May 2019).

7. Toronto Public Health. @TOPublicHealth. (Toronto Public Health, Toronto, ON, 2020).

8. CBC News. Toronto opens new safe injection site at Fred Victor Centre. in *CBC News* (Toronto, ON, 2018).

9. Toronto Central Health Line. Queen and Jarvis Site - Supervised Consumption Service. (Toronto, ON, 2021).

10. Fred Victor. Fred Victor's response to the COVID-19 pandemic. (Toronto, ON, 2020).

11. Pride Toronto. Community Resources in Response to COVID-19. (2020).

12. Mullin, M. Citing overdose 'crisis' police to allow unsanctioned Toronto injection site. in *CBC News* (Toronto, ON, 2017).

13. Contenta, S. Toronto Star: Overdose prevention workers save thousands of lives, but who's saving theirs? (South Riverdale Community Health Centre, Toronto, ON, 2019).

14. CTVNews.ca Staff. Unsanctioned pop-up safe-injection site opens in Toronto. in *CTV News* (Toronto, ON, 2017).

15. News Staff. Safe injection site opens in Parkdale. in *CityNews* (Toronto, ON, 2018).

16. Parkdale Queen West Community Health Centre. Hours, Location & Phone Numbers. (2018).

17. City of Toronto. Supervised Consumption Services. (Toronto, ON, 2021).

18. Parkdale Queen West Community Health Centre. Supervised Consumption Services (SCS) - Queen West Site. (Toronto, ON, 2020).

19. Parkdale Queen West Community Health Centre. Frequently Asked Questions (FAQ) about the Overdose Prevention Site at Parkdale. (Parkdale Queen West Community Health Centre, Toronto, ON, 2018).

20. Toronto Central Health Line. Parkdale Queen West Community Health Centre - Parkdale Site. (Toronto, ON, 2021).

21. Jones, R.P. New temporary safe injection sites open in Kensington, Regent Park. in *CBC News* (Toronto, ON, 2018).

22. Regent Park Community Health Centre. OPS Pamphlet. (ed. Centre, R.P.C.H.) (Toronto, ON, 2020).

23. Kolla, G., Penn, R. & Long, C. Evaluation of the Overdose Prevention Sites at Street Health and St. Stephen's Community House. (Street Health and St. Stephen's Community House, Toronto, ON, 2019).

24. Street Health Community Health Centre. Street Health Overdose Prevention Site. (ed. Health, S.) (2018).

25. Toronto Drop-In Network. Evaluation of the Overdose Prevention Services at St. Stephen's Community House and Street Health. (Toronto, ON, 2020).

26. St. Stephen's Community House. Temporary overdose prevention site at 260 Augusta Ave. (St. Stephen's Community House Toronto, Toronto, ON, 2018).

27. City of Hamilton. Consumption and Treatment Services (CTS). (2018).

28. Hamilton Urban Core Community Health Centre. Consumption & Treatment Service. Vol. 2021 (Hamilton, ON, 2018).

29. Hamilton Public Library. Overdose Prevention Site. (Community Information by Hamilton Public Library, Hamilton, ON, 2020).

30. Hurdle, L. Consumption and Treatment Services - Street Health Centre. (City of Kingston, Kingston, ON, 2019).

31. Ferguson, E. Ministry to set up overdose prevention site. in *The Kingston Whig Standard* (Kingston, ON, 2018).

32. Kingston Frontenac Lennox and Addincton Public Health. Consumption and Treatment Services. (KFLAPH, 2020).

33. Middlesex-London Health Unit. Temporary Overdose Prevention Site (TOPS). (Middlesex-London Health Unit, London, ON, 2018).

34. CBC News. Take a tour of London's Temporary Overdose Prevention Site. in *CBC News* (Toronto, ON, 2018).

35. Kitching, S. Overdose Prevention Site to Open Monday. (Blackburn News, London, ON, 2018).

36. Lupton, A. COVID-19 puts new focus on space constraints at London's drug-use site. (CBC News, London, ON, 2020).

37. Clementson, L. St. Catharines home to first supervised consumption site in Niagara region. (CBC News, St. Catherines, ON, 2019).

38. The Welland Tribune. Positive living Niagara facing challenges during pandemic. in *Niagara Falls Review* (Niagara Region, 2020).

39. Ottawa Prevention. Overdose Prevention Ottawa Summary Report. (Ottawa, ON, 2018).

40. Raymond, T. Ottawa Public Health to expand supervised consumption services at Clarence Street. in *CTV News* (Ottawa, ON, 2018).

41. CBC News. Injection site scaling back hours due to funding shortfall. in *CBC News* (Ottawa, ON, 2019).

42. Crawford, B. City's first permanent supervised injection site opens at Sandy Hill Community Health Centre. in *Ottawa Citizen* (Ottawa, ON, 2018).

43. Jones, R.P. Injection sites scales back physical distancing rules to prevent ODs. in *CBC News* (Ottawa, ON, 2020).

44. DelVillano, S., de Groh, M., Morrison, H. & Do, M.T. At-a-glance - Supervised Injection Services: a community-based response to the opioid crisis in the City of Ottawa, Canada. *Health promotion and chronic disease prevention in Canada: research, policy and practice* **39**, 112-115 (2019).

45. Payne, E. Province supports new Inner City Health supervised injection site. in *Ottawa Citizen* (Ottawa, ON, 2017).

46. Fagan, L. ByWard Market supervised injeciton trailer to get permanent home. in *CBC News* (Ottawa, ON, 2019).

47. Reynolds, C. Supervised injection sites across Canada hampered by COVID-19. in *The Canadian Press* (2021).

48. Whan, C. New temporary overdose prevention site opens in Somerset West. in *Global News* (Ottawa, ON, 2018).

49. Raymond, T. Somerset West CHC launches new supervised drug consumption site. in *CTV News* (Ottawa, ON, 2018).

50. Pivot Legal Society. Canada's supervised consumption and overdose prevention sites. (Pivot Legal Society, Vancouver, BC, 2020).

51. Pivot Legal Society. Canada's Supervised Consumption and Overdose Prevention Sites. (Vancouver, BC, 2019).

52. Diaczuk, D. Overdose prevention site now open. in *TBnewswatch* (Thunder Bay, ON, 2018).

53. NorWest Community Health Centres. NorWest CHC is expanding its harm reduction services. (24 March 2020).

54. 211 Ontario North. Norwest community health centres: Path 525. (Thunder Bay, ON, 2020).

55. Groleau, C. Overdose prevention site in Guelph logs 430 visits since opening. in *CBC News* (Kitchener-Waterloo, ON, 2018).

56. Wellington-Duffering-Guelph, P.H. Where to get take-home naloxone kits. (2018).

57. Armstrong, K. Guelph safe injection site to double its capacity. in *GuelphToday* (Guelph, ON, 2020).

58. Centre, G.C.H. Reduced Health Services Hours. (Guelph, ON, 2020).

59. CBC News. Here's what Kitchener's consumption treatment site looks like. in *CBC News* (Kitchener-Waterloo, 2019).

60. Senoran, H. Permanent CTS site coming to downtown Kitchener one year after temporary site opened. in *CTV News* (Kitchener, ON, 2020).

61. The Corporation of the City of Sault Ste. Marie. Council Correspondence. (City of Sault Ste. Marie, Sault Ste. Maria, ON, 2019).

62. Kelly, B. Overdose does not discriminate. in *The Brantford Expositor* (Sault Ste. Marie, ON, 2019).

63. The Sault Star. News briefs. in *The Sault Star* (Sault Ste. Marie, 2019).

64. Brant County Health Unit. Annual Report 2017. (2017).

65. Brant County Board of Health. Regular Agenda. in *Opioid Surveillance* (Brant County, ON, 2018).

66. Brant County Health Unit. Brant/Brantford Opioid Information System. (Brant County, ON, 2021).

67. Chatham - Kent Public Health. Annual Report 2017. (Chatham, ON, 2017).

68. Municipality of Chatham-Kent. Improvements for CK Public Health's Harm Reduction Program. in *Community Human Services - Public Health Unit* (Chatham, ON, 2021).

69. Chatham - Kent Public Health. Opioid Surveillance Summary. (2021).

70. City of Hamilton. Hamilton Opioid Information System - Naloxone. (Hamilton, ON, 2021).

71. Paddon, N. Public health handing out more naloxone kits. in *The Hamilton Spectator* (Hamilton, ON, 2018).

72. Tadrous, M., Shearer, D., Martins, D., Campbell, T. & Gomes, T. Naloxone Distribution Across Ontario. (Ontario Drug Policy Research Network, Toronto, ON, 2019).

73. Public Health Grey Bruce. Grey Bruce Opioid Response Plan. (Grey Bruce, ON, 2020).

74. Public Health Grey Bruce. Opioid Situation Report #1. (Grey Bruce, ON, 2021).

75. Health and Social Services Haldimand and Norfolk. Health Unit Opioid Management Plan. (Haldimand Norfolk Health and Social Services, Haldimand, ON, 2018).

76. Haliburton, K., Pine Ridge District Health Unit. 2019 Annual Report: Strong Roots in our Communities. (Ontario, 2020).

77. Halton Region. Opioid Reporting. (ed. Halton Region) (2021).

78. Hastings Prince Edward County Public Health. The impact of opioids and other drugs in Hastings and Prince Edward Counties. (Hastings Prince Edward Public Health, Belleville, ON, 2019).

79. Hastings Prince Edward County Public Health. 2019 Annual Report. (Hastings Prince Edward Public Health, Belleville, ON, 2021).

80. Kingston Community Health Centres. Annual Report 2017/18 Moving Upstream: Addressing the Social Determinants of Health. (Kingston, ON, 2019).

81. Lambton Public Health. 2018 Annual Report. (Lambton, ON, 2019).

82. Ontario Association of Fire Chiefs. Analysis: Deep in the opioid crisis in Southwestern Ontario. (2020).

83. Middlesex-London Health Unit. Opioids - What is the situation? (Middlesex-London Health Unit, London, ON, 2021).

84. Niagara Region. Naloxone use and distribution in Niagara (2019 - 2021). (St. Catherines, ON, 2021).

85. CBC News. Naloxone use on the rise in Thunder Bay, health unit says. in *CBC News* (Thunder Bay, ON, 2019).

86. Northwestern Health Unit. 2017 Public Health Report Card. (Northwestern Public Health, 2020).

87. Northwestern Health Unit. Moving Forward: 2018 Public Health Report Card. (Northwestern Public Health, 2020).

88. Ottawa Board of Health. Subject: Next steps in harm reduction and overdose prevention. (Ottawa Public Health, Ottawa, ON, 2019).

89. Ottawa Public Health. 2017 Annual Report. (Ottawa Public Health, Ottawa, ON, 2018).

90. Ottawa Public Health. Subject: Ottawa overdose prevention and response task force: Update. (Ottawa Public Health, Ottawa, ON, 2017).

91. Region of Peel. Peel Opioid Strategy: A local response. (2019).

92. Porcupine health unit. 2017 Annual Report. (2018).

93. Porcupine health unit. Medical officer of health report to the board of health. (Porcupine Public Health, 2020).

94. Renfrew County and District Health Unit. 2017 Annual Report. (2018).

95. Renfrew County and District Health Unit. 2018 Annual Report. (2019).

96. Renfrew County and District Health Unit. 2019 Annual Report. (2020).

97. Simcoe Muskoka District Health Unit. 2018 Status Update. in *Simcoe Muskoka Opioid Strategy* (2019).

98. Simcoe Muskoka District Health Unit. Simcoe Muskoka Opioid Strategy Scorecard. (2020).

99. Public Health Sudbury District. A study to explore the need for and feasibility of implementing supervised consumption services in the City of Greater Sudbury. (Public Health Sudbury District, 2021).

100. Public Health Sudbury District. Naloxone Distribution. (2021).

101. Thunder Bay District Health Unit. Opioid Information System. (2021).

102. Medical Officer of Health. Toronto Overdose Action Plan: Status Report 2019. in *Report for Action*, Vol. HL7.1 (City of Toronto, Toronto, ON, 2019).

103. Medical Officer of Health. Toronto Overdose Action Plan: Status Report 2020. in *Report for Action*, Vol. HL17.2 (City of Toronto, Toronto, ON, 2020).

104. Medical Officer of Health. Toronto Overdose Action Plan: Status Report 2021. in *Report for Action* (City of Toronto, Toronto, ON, 2021).

105. Region of Waterloo. Waterloo Region Supervised Injection Services Feasibility Study. (Waterloo, ON, 2018).

106. Regional Municipality of Waterloo. Harm Reduction Planning, Programs and Services Update. Vol. P03-20 (Region of Waterloo, Waterloo, ON, 2019).

107. Wellington-Dufferin-Guelph, P.H. Naloxone Distribution Program. (2019).

108. Windsor-Essex County Health Unit. Opioid Overdose Statistics. (2021).

109. Regional Municipality of York. York Region Public Health's Opioid Action Plan. (2019).

Table 2. Synthetic control predictor weights

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Toronto**  | **Hamilton** | **Kingston** | **London** | **Niagara** |
| **Predictor** | **ED** | **Hosp** | **Deaths** | **ED** | **Hosp** | **Deaths** | **ED** | **Hosp** | **Deaths** | **ED** | **Hosp** | **Deaths** | **ED** | **Hosp** | **Deaths** |
| Alcohol-related ED visit rate (per 100,000 pop.) | 0.01 | 0.05 | 0.18 | 0.02 | 0.2 | 0.05 | 0.05 | 0.41 | 0.19 | 0.01 | 0.01 | 0.06 | 0.02 |  | 0.12 |
| Alcohol-related hospitalization rate (per 100,000 pop.) | 0.13 | 0.14 | 0.02 | 0.03 |  | 0.11 | 0.01 | 0.54 | 0.01 | 0.28 | 0.19 | 0.15 |  | 0.21 | 0.06 |
| Patients prescribed opioids for pain (per 1000 pop.) | 0.26 |  |  | 0.65 | 0.17 |  |  | 0.04 | 0.27 | 0.13 | 0.34 | 0.05 |  |  |  |
| Naloxone kits distributed (per 1000 pop.) | 0.02 | 0.05 | 0.09 | 0.02 |  | 0.1 |  |  | 0.25 |  | 0.23 |  | 0.31 |  |  |
| Persons receiving OAT (per 1000 pop.) | 0.26 | 0.01 | 0.12 | 0.18 |  | 0.27 | 0.04 |  | 0.06 | 0.22 |  |  |  | 0.28 | 0.36 |
| Median household income | 0.05 | 0.27 | 0.25 | 0.01 |  | 0.16 | 0.11 |  | 0.01 |  |  |  |  |  | 0.02 |
| Proportion pop. low income  |  |  | 0.07 | 0.06 | 0.44 | 0.12 | 0.33 |  | 0.19 | 0.16 | 0.05 | 0.61 | 0.18 | 0.35 |  |
| Proportion pop. Unemployed | 0.18 |  | 0.07 | 0.04 |  | 0.07 | 0.45 |  | 0.02 |  |  |  | 0.25 | 0.16 | 0.14 |
| Proportion adult pop. w/o high school degree | 0.07 | 0.44 | 0.18 |  | 0.19 | 0.05 | 0.01 |  |  | 0.01 |  | 0.07 | 0.24 |  | 0.28 |
| Proportion visible minority | 0.02 | 0.04 | 0.02 |  |  | 0.06 |  |  | 0.01 | 0.18 | 0.18 | 0.04 |  |  | 0.01 |
| **Predictor** | **Ottawa** | **Thunder Bay** | **Guelph** | **Waterloo** |
| Alcohol-related ED visit rate (per 100,000 pop.) | 0.09 | 0.13 | 0.04 | 0.09 |  |  | 0.17 | 0.06 | 0.04 | 0.01 | 0.01 | 0.03 |
| Alcohol-related hospitalization rate (per 100,000 pop.) | 0.01 | 0.01 | 0.02 | 0.01 |  |  |  | 0.01 | 0.01 | 0.76 | 0.08 |  |
| Patients prescribed opioids for pain (per 1000 pop.) | 0.12 | 0.01 | 0.02 | 0.12 | 0.51 |  |  | 0.36 | 0.34 |  |  | 0.17 |
| Naloxone kits distributed (per 1000 pop.) |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.01 |
| Persons receiving OAT (per 1000 pop.) | 0.02 | 0.01 | 0.02 | 0.02 |  |  | 0.36 | 0.07 | 0.16 | 0.01 |  | 0.01 |
| Median household income | 0.2 | 0.36 | 0.71 | 0.2 | 0.13 |  | 0.21 | 0.04 | 0.34 |  | 0.81 | 0.02 |
| Proportion pop. low income  |  | 0.02 | 0.07 |  |  | 0.03 | 0.25 | 0.26 |  | 0.18 | 0.03 |  |
| Proportion pop. Unemployed | 0.52 | 0.42 | 0.06 | 0.52 |  | 0.68 |  |  | 0.05 |  |  | 0.46 |
| Proportion adult pop. w/o high school degree | 0.03 | 0.03 | 0.05 | 0.03 | 0.34 | 0.25 |  | 0.17 | 0.07 | 0.03 | 0.06 |  |
| Proportion visible minority |  | 0.01 | 0.01 |  | 0.01 | 0.03 |  | 0.04 |  |  |  | 0.29 |

Pop.=population; w/o=without

Table 3. Synthetic control donor public health units

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Toronto | Hamilton | Kingston | London | Niagara | Ottawa | Thunder Bay | Guelph | Waterloo |
| Public Health Unit | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths | ED | Hosp | Deaths |
| Algoma |  |  | 0.07 |  | 0.06 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Brant County |  |  |  | 0.22 | 0.06 |  | 0.15 | 0.13 | 0.11 |  | 0.01 |  | 0.15 | 0.13 | 0.03 |  |  |  | 0.18 | 0.05 | 0.35 | 0.06 |  | 0.28 | 0.20 |  | 0.23 |
| Chatham-Kent |  |  |  |  | 0.04 |  |  |  |  |  | 0.16 | 0.24 |  | 0.12 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Durham Region |  | 0.10 |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.12 | 0.10 | 0.13 |  |  |  |  |  |  |  |  |  |
| Eastern Ontario |  |  |  |  | 0.18 |  |  |  | 0.07 |  | 0.19 |  |  | 0.02 |  |  |  | 0.01 |  |  |  | 0.09 | 0.19 |  |  | 0.12 |  |
| Grey Bruce |  |  |  | 0.10 | 0.02 |  |  |  | 0.22 |  |  |  | 0.07 | 0.05 |  |  |  |  |  |  |  | 0.11 | 0.08 | 0.26 | 0.29 |  | 0.04 |
| Haldimand-Norfolk |  |  |  | 0.12 |  | 0.10 |  |  |  |  |  |  |  | 0.01 |  |  |  |  |  | 0.10 |  | 0.09 | 0.07 |  |  |  |  |
| Haliburton-Kawartha-Pine Ridge |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Halton Region |  | 0.06 |  |  |  |  | 0.04 |  |  |  |  |  |  |  | 0.15 | 0.04 | 0.18 |  |  |  |  | 0.38 | 0.33 | 0.08 | 0.25 |  | 0.62 |
| Hastings Prince Edward |  |  |  |  | 0.01 |  |  |  |  |  |  |  | 0.11 | 0.08 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lambton |  |  |  |  | 0.01 |  |  |  |  |  | 0.21 |  |  | 0.01 |  |  |  |  |  |  |  |  |  |  |  | 0.05 |  |
| Leeds-Grenville-Lark |  |  | 0.12 |  | 0.01 |  |  | 0.10 |  |  |  | 0.34 | 0.01 | 0.01 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| North Bay Parry Sound |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.02 |  |  |  |  | 0.57 | 0.21 |  |  |  |  |  |  |  |
| Northwestern | 0.22 |  |  | 0.08 | 0.03 |  |  | 0.03 | 0.04 | 0.29 | 0.14 |  |  |  |  |  |  |  |  | 0.25 | 0.33 | 0.04 | 0.08 | 0.01 |  |  |  |
| Peel | 0.36 | 0.47 | 0.41 |  |  |  |  |  | 0.06 | 0.15 | 0.23 | 0.06 |  |  |  | 0.27 | 0.29 | 0.13 |  |  |  |  |  |  |  | 0.53 |  |
| Peterborough |  |  |  | 0.12 | 0.11 |  | 0.22 | 0.12 | 0.13 | 0.21 |  | 0.17 | 0.64 | 0.43 | 0.14 |  |  |  |  | 0.18 | 0.07 |  |  |  |  | 0.02 |  |
| Porcupine |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Renfrew |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.02 |  |  |  |  |  |  |  |  |  |  |  | 0.01 |  |
| Simcoe Muskoka | 0.22 |  | 0.24 | 0.30 | 0.38 | 0.38 | 0.27 | 0.07 | 0.31 |  |  |  |  | 0.01 | 0.23 | 0.20 | 0.09 | 0.09 |  |  |  | 0.21 | 0.01 | 0.03 | 0.04 | 0.01 |  |
| Sudbury |  |  |  | 0.06 | 0.01 | 0.28 | 0.06 | 0.31 | 0.05 | 0.35 | 0.06 |  |  |  | 0.25 |  |  |  | 0.24 | 0.08 | 0.25 |  | 0.12 |  | 0.22 | 0.14 | 0.09 |
| Timiskaming |  |  |  |  | 0.01 |  |  |  |  |  |  |  |  | 0.01 |  |  |  |  |  | 0.12 |  |  |  |  |  |  |  |
| Windsor-Essex |  | 0.08 | 0.15 |  | 0.04 | 0.24 | 0.26 | 0.06 |  |  |  | 0.19 | 0.01 | 0.03 | 0.18 |  | 0.14 | 0.14 |  |  |  |  |  |  |  | 0.10 |  |
| York | 0.21 | 0.28 |  |  |  |  |  | 0.17 |  |  |  |  |  |  |  | 0.36 | 0.20 | 0.50 |  |  |  |  | 0.12 | 0.35 |  |  | 0.02 |
| PHU with non-zero weights | 4 | 5 | 5 | 7 | 18 | 4 | 6 | 8 | 8 | 4 | 7 | 5 | 4 | 16 | 6 | 5 | 6 | 6 | 3 | 7 | 4 | 7 | 8 | 6 | 5 | 8 | 5 |

Table 4. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Emergency department visits  | Hospitalizations  | Deaths |  |
|  | Crude (95% CI) | P-value | Adj.\* (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value |
| Toronto |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.03 (1.02, 1.05) | <0.0001 | 1.03 (1.01, 1.05) | 0.0026 | 1.01 (1.00, 1.01) | 0.0978 | 1.01 (1.00, 1.01) | 0.0624 | 1.02 (1.01, 1.03) | 0.0019 | 1.02 (1.01, 1.03) | 0.0020 |
|  Pre-intervention level difference, treated (β2) | 1.11 (0.70, 1.76) | 0.6483 | 1.23 (0.59, 2.54) | 0.5787 | 1.64 (0.98, 2.73) | 0.0603 | 1.47 (0.89, 2.45) | 0.1338 | 1.22 (0.81, 1.82) | 0.3426 | 1.27 (0.84, 1.91) | 0.2537 |
|  Pre-intervention trend difference, treated (β3) | 1.01 (0.99, 1.03) | 0.1921 | 1.01 (0.99, 1.04) | 0.3320 | 1.02 (1.00, 1.05) | 0.0450 | 1.02 (1.00, 1.04) | 0.1124 | 1.01 (0.99, 1.03) | 0.2242 | 1.01 (0.99, 1.03) | 0.2338 |
|  Post-intervention level difference, synthetic control (β4) | 0.99 (0.77, 1.29) | 0.9643 | 1.08 (0.76, 1.54) | 0.6633 | 1.11 (0.89, 1.38) | 0.3533 | 1.16 (0.96, 1.40) | 0.1143 | 1.16 (0.85, 1.57) | 0.3498 | 1.24 (0.97, 1.59) | 0.0811 |
|  Post-intervention trend difference, synthetic control (β5) | 0.98 (0.97, 1.00) | 0.0063 | 0.98 (0.97, 1.00) | 0.0688 | 0.99 (0.98, 1.00) | 0.0444 | 0.99 (0.98, 1.00) | 0.0293 | 1.00 (0.99, 1.02) | 0.8580 | 1.00 (0.98, 1.02) | 0.8461 |
|  Post-intervention level difference, treated (β6) | 1.27 (0.88, 1.85) | 0.2037 | 1.25 (0.78, 2.02) | 0.3546 | 0.97 (0.69, 1.38) | 0.8768 | 1.01 (0.74, 1.39) | 0.9368 | 1.15 (0.74, 1.80) | 0.5426 | 1.13 (0.77, 1.68) | 0.5295 |
|  Post-intervention trend difference, treated (β7) | 0.98 (0.96, 1.00) | 0.0718 | 0.99 (0.96, 1.02) | 0.3907 | 0.97 (0.93, 1.01) | 0.1324 | 0.98 (0.94, 1.02) | 0.3314 | 1.00 (0.98, 1.02) | 0.9995 | 1.00 (0.98, 1.03) | 0.8461 |
|  Per 100 booth-hours | 0.94 (0.82, 1.06) | 0.3089 | 0.98 (0.75, 1.28) | 0.8871 | 0.99 (0.86, 1.15) | 0.9210 | 1.01 (0.89, 1.16) | 0.8520 | 0.86 (0.73, 1.01) | 0.0633 | 0.88 (0.69, 1.12) | 0.2887 |
|  Per 100 OAT recipients | 1.00 (0.84, 1.18) | 0.9751 | 1.04 (0.81, 1.34) | 0.7422 | 0.02 (0.00, 1.51) | 0.0768 | 0.07 (0.00, 3.88) | 0.1916 | 0.98 (0.74, 1.29) | 0.8788 | 1.03 (0.72, 1.47) | 0.8881 |
|  Per 100 naloxone kits dispensed | 0.98 (0.78, 1.23) | 0.8750 | 0.86 (0.62, 1.21) | 0.3915 | 0.88 (0.70, 1.12) | 0.3102 | 0.81 (0.65, 1.02) | 0.0681 | 0.73 (0.55, 0.96) | 0.0226 | 0.68 (0.45, 1.00) | 0.0706 |
| Hamilton |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.03 (1.01, 1.04) | <0.0001 | 1.03 (1.01, 1.04) | 0.0009 | 1.01 (0.99, 1.02) | 0.3320 | 1.01 (1.00, 1.01) | 0.2010 | 1.00 (0.97, 1.03) | 0.8337 | 1.00 (0.97, 1.03) | 0.8696 |
|  Pre-intervention level difference, treated (β2) | 0.93 (0.62, 1.38) | 0.7064 | 0.89 (0.55, 1.44) | 0.6374 | 1.05 (0.80, 1.36) | 0.7390 | 1.05 (0.87, 1.28) | 0.5944 | 2.82 (1.14, 6.94) | 0.0244 | 2.84 (1.08, 7.44) | 0.0341 |
|  Pre-intervention trend difference, treated (β3) | 1.00 (0.98, 1.01) | 0.8229 | 1.00 (0.98, 1.02) | 0.8884 | 0.99 (0.98, 1.01) | 0.3542 | 0.99 (0.98, 1.00) | 0.1733 | 1.03 (1.00, 1.05) | 0.0269 | 1.03 (1.01, 1.05) | 0.0059 |
|  Post-intervention level difference, synthetic control (β4) | 0.88 (0.68, 1.13) | 0.3115 | 0.91 (0.60, 1.40) | 0.6801 | 0.83 (0.63, 1.10) | 0.1965 | 0.82 (0.68, 0.98) | 0.0330 | 0.96 (0.62, 1.47) | 0.8459 | 0.96 (0.64, 1.44) | 0.8500 |
|  Post-intervention trend difference, synthetic control (β5) | 0.99 (0.98, 1.00) | 0.1324 | 0.99 (0.97, 1.01) | 0.2460 | 0.99 (0.98, 1.01) | 0.5125 | 0.99 (0.99, 1.00) | 0.0784 | 1.03 (1.00, 1.06) | 0.0311 | 1.03 (1.01, 1.06) | 0.0165 |
|  Post-intervention level difference, treated (β6) | 2.60 (1.06, 6.37) | 0.0364 | 2.45 (0.90, 6.68) | 0.0790 | 1.06 (0.37, 3.05) | 0.9095 | 0.94 (0.32, 2.81) | 0.9189 | 3.58 (0.89, 14.47) | 0.0735 | 3.54 (0.60, 21.04) | 0.1639 |
|  Post-intervention trend difference, treated (β7) | 0.97 (0.94, 0.99) | 0.0125 | 0.97 (0.94, 1.00) | 0.0560 | 1.01 (0.98, 1.04) | 0.4588 | 1.02 (0.99, 1.04) | 0.1829 | 0.93 (0.90, 0.96) | <0.0001 | 0.93 (0.90, 0.96) | <0.0001 |
|  Per 100 booth-hours | 0.65 (0.40, 1.05) | 0.0754 | 0.68 (0.43, 1.08) | 0.1041 | 1.01 (0.98, 1.77) | 0.9993 | 1.08 (0.62, 1.86) | 0.7908 | 0.48 (0.23, 0.99) | 0.0484 | 0.48 (0.19, 1.21) | 0.1212 |
|  Per 100 OAT recipients | 0.94 (0.76, 1.16) | 0.5432 | 0.91 (0.77, 1.08) | 0.2630 | 1.06 (0.83, 1.35) | 0.6448 | 1.10 (0.94, 1.28) | 0.2503 | 1.47 (0.86, 2.52) | 0.1558 | 1.48 (0.80, 2.73) | 0.2157 |
|  Per 100 naloxone kits dispensed | 1.08 (0.98, 1.20) | 0.1132 | 1.04 (0.89, 1.21) | 0.6171 | 1.01 (0.89, 1.14) | 0.8653 | 1.01 (0.85, 1.20) | 0.9125 | 1.05 (0.91, 1.22) | 0.5078 | 1.03 (0.89, 1.20) | 0.6850 |
| Kingston |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.01 (0.99, 1.03) | 0.2881 | 1.01 (1.00, 1.03) | 0.1351 | 0.99 (0.97, 1.02) | 0.6166 | 1.00 (0.97, 1.03) | 0.8390 | 1.02 (0.99, 1.05) | 0.2436 | 1.02 (1.00, 1.04) | 0.0429 |
|  Pre-intervention level difference, treated (β2) | 1.50 (0.80, 2.81) | 0.2096 | 1.64 (0.93, 2.91) | 0.0885 | 1.57 (0.78, 3.17) | 0.2038 | 1.50 (0.71, 3.15) | 0.2833 | 1.03 (0.59, 1.80) | 0.9241 | 1.06 (0.63, 1.79) | 0.8267 |
|  Pre-intervention trend difference, treated (β3) | 1.02 (1.00, 1.04) | 0.1033 | 1.02 (1.00, 1.04) | 0.0980 | 1.01 (0.99, 1.04) | 0.2934 | 1.01 (0.98, 1.04) | 0.4173 | 1.00 (0.97, 1.03) | 0.9817 | 1.00 (0.98, 1.02) | 0.8725 |
|  Post-intervention level difference, synthetic control (β4) | 0.91 (0.66, 1.25) | 0.5574 | 0.96 (0.70, 1.32) | 0.8235 | 0.60 (0.35, 1.05) | 0.0718 | 0.59 (0.35, 0.99) | 0.0457 | 0.89 (0.50, 1.59) | 0.6964 | 0.91 (0.66, 1.25) | 0.5424 |
|  Post-intervention trend difference, synthetic control (β5) | 1.00 (0.97, 1.02) | 0.7121 | 1.00 (0.98, 1.01) | 0.7388 | 0.98 (0.96, 1.01) | 0.2405 | 0.99 (0.96, 1.01) | 0.1884 | 1.01 (0.98, 1.04) | 0.6871 | 1.01 (0.99, 1.02) | 0.3884 |
|  Post-intervention level difference, treated (β6) | 0.43 (0.14, 1.29) | 0.1324 | 0.50 (0.16, 1.53) | 0.2232 | 1.18 (0.18, 7.74) | 0.8612 | 1.67 (0.29, 9.71) | 0.5700 | 0.68 (0.11, 4.03) | 0.6711 | 0.70 (0.14, 3.51) | 0.6675 |
|  Post-intervention trend difference, treated (β7) | 0.97 (0.94, 1.00) | 0.0318 | 0.97 (0.94, 1.00) | 0.0327 | 0.97 (0.93, 1.01) | 0.1022 | 0.97 (0.92, 1.02) | 0.2241 | 0.98 (0.94, 1.03) | 0.3905 | 0.98 (0.95, 1.02) | 0.2997 |
|  Per 100 booth-hours | 1.24 (0.90, 1.70) | 0.1879 | 1.17 (0.86, 1.59) | 0.3170 | 1.11 (0.64, 1.92) | 0.7011 | 1.00 (0.60, 1.65) | 0.9961 | 1.18 (0.71, 1.97) | 0.5272 | 1.15 (0.73, 1.80) | 0.5437 |
|  Per 100 OAT recipients | 1.21 (0.79, 1.86) | 0.3817 | 1.28 (0.97, 1.70) | 0.0813 | 1.30 (0.84, 2.02) | 0.2357 | 1.25 (0.81, 1.93) | 0.3168 | 1.10 (0.70, 1.71) | 0.6864 | 1.18 (0.95, 1.46) | 0.1372 |
|  Per 100 naloxone kits dispensed | 1.24 (1.02, 1.50) | 0.0333 | 1.17 (0.95, 1.44) | 0.1484 | 1.39 (1.02, 1.91) | 0.0376 | 1.34 (0.88, 2.05) | 0.1776 | 1.08 (0.78, 1.51) | 0.6309 | 1.03 (0.76, 1.41) | 0.8293 |
| London |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.02 (1.00, 1.04) | 0.0156 | 1.02 (1.01, 1.04) | 0.0101 | 1.01 (0.99, 1.02) | 0.4538 | 1.00 (0.99, 1.02) | 0.4024 | 1.04 (1.00, 1.08) | 0.0271 | 1.04 (1.01, 1.07) | 0.0198 |
|  Pre-intervention level difference, treated (β2) | 1.56 (0.86, 2.85) | 0.1452 | 1.65 (0.80, 3.38) | 0.1740 | 1.25 (0.89, 1.75) | 0.1922 | 1.26 (0.97, 1.63) | 0.0875 | 1.51 (0.81, 2.79) | 0.1936 | 1.47 (0.80, 2.73) | 0.2176 |
|  Pre-intervention trend difference, treated (β3) | 1.02 (1.00, 1.04) | 0.1103 | 1.02 (1.00, 1.04) | 0.0741 | 1.01 (0.99, 1.02) | 0.4489 | 1.01 (0.99, 1.02) | 0.3108 | 0.99 (0.96, 1.02) | 0.5560 | 0.99 (0.96, 1.03) | 0.6388 |
|  Post-intervention level difference, synthetic control (β4) | 1.17 (0.86, 1.60) | 0.3150 | 1.14 (0.68, 1.91) | 0.6133 | 0.84 (0.60, 1.18) | 0.3171 | 0.85 (0.64, 1.13) | 0.2670 | 0.81 (0.47, 1.39) | 0.4363 | 0.79 (0.45, 1.38) | 0.4055 |
|  Post-intervention trend difference, synthetic control (β5) | 1.01 (0.99, 1.02) | 0.3272 | 1.01 (0.99, 1.03) | 0.3781 | 1.01 (0.99, 1.02) | 0.3081 | 1.01 (1.00, 1.02) | 0.1021 | 0.99 (0.95, 1.02) | 0.4378 | 0.99 (0.95, 1.02) | 0.4918 |
|  Post-intervention level difference, treated (β6) | 1.31 (0.81, 2.13) | 0.2763 | 1.24 (0.58, 2.61) | 0.5792 | 1.76 (1.01, 3.08) | 0.0460 | 1.75 (1.12, 2.73) | 0.0148 | 1.77 (0.77, 4.08) | 0.1767 | 1.62 (0.72, 3.65) | 0.2472 |
|  Post-intervention trend difference, treated (β7) | 0.98 (0.95, 1.00) | 0.0370 | 0.98 (0.95, 1.00) | 0.0617 | 0.97 (0.95, 0.99) | 0.0112 | 0.97 (0.95, 0.99) | 0.0024 | 1.00 (0.97, 1.03) | 0.9742 | 1.00 (0.96, 1.04) | 0.9421 |
|  Per 100 booth-hours | 0.78 (0.66, 0.92) | 0.0029 | 0.80 (0.65, 1.00) | 0.0489 | 0.87 (0.69, 1.10) | 0.2390 | 0.87 (0.72, 1.05) | 0.1555 | 0.79 (0.60, 1.04) | 0.0903 | 0.83 (0.63, 1.09) | 0.1864 |
|  Per 100 OAT recipients | 1.07 (0.89, 1.30) | 0.4693 | 1.09 (0.86, 1.39) | 0.4621 | 1.00 (0.77, 1.32) | 0.9745 | 1.02 (0.83, 1.27) | 0.8269 | 0.62 (0.30, 1.25) | 0.1812 | 0.66 (0.40, 1.08) | 0.1002 |
|  Per 100 naloxone kits dispensed | 0.93 (0.84, 1.03) | 0.1622 | 0.92 (0.78, 1.08) | 0.3192 | 0.80 (0.69, 0.92) | 0.0018 | 0.80 (0.71, 0.91) | 0.0004 | 0.94 (0.79, 1.12) | 0.4863 | 0.93 (0.72, 1.21) | 0.5923 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Emergency department visits  | Hospitalizations  | Deaths |  |
|  | Crude (95% CI) | P-value | Adj.\* (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value |
| Niagara |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.00 (0.98, 1.02) | 0.7524 | 1.01 (0.98, 1.03) | 0.6716 | 1.00 (0.98, 1.01) | 0.8337 | 1.00 (0.99, 1.01) | 0.6224 | 1.04 (1.01, 1.06) | 0.0027 | 1.04 (1.02, 1.06) | 0.0002 |
|  Pre-intervention level difference, treated (β2) | 1.58 (1.17, 2.14) | 0.003 | 1.57 (1.18, 2.08) | 0.0017 | 1.47 (0.99, 2.19) | 0.0573 | 1.46 (1.06, 2.02) | 0.0199 | 1.95 (1.18, 3.20) | 0.0087 | 1.97 (1.38, 2.80) | 0.0002 |
|  Pre-intervention trend difference, treated (β3) | 1.01 (1.00, 1.03) | 0.1207 | 1.01 (1.00, 1.03) | 0.1111 | 1.01 (1.00, 1.03) | 0.0806 | 1.01 (1.00, 1.03) | 0.0354 | 0.99 (0.97, 1.01) | 0.4977 | 0.99 (0.97, 1.01) | 0.3834 |
|  Post-intervention level difference, synthetic control (β4) | 0.99 (0.71, 1.37) | 0.9375 | 0.98 (0.65, 1.48) | 0.9336 | 0.75 (0.51, 1.10) | 0.1370 | 0.79 (0.65, 0.96) | 0.0186 | 0.64 (0.42, 0.96) | 0.0327 | 0.64 (0.43, 0.94) | 0.0231 |
|  Post-intervention trend difference, synthetic control (β5) | 1.00 (0.98, 1.03) | 0.7361 | 1.00 (0.97, 1.03) | 0.8525 | 1.01 (0.98, 1.03) | 0.6111 | 1.01 (0.99, 1.02) | 0.4268 | 1.00 (0.97, 1.02) | 0.8304 | 1.00 (0.98, 1.01) | 0.6349 |
|  Post-intervention level difference, treated (β6) | 22.50 (4.08, 124.13) | 0.0004 | 14.42 (2.31, 89.94) | 0.0043 | 5.10 (0.50, 52.46) | 0.1703 | 4.50 (0.44, 45.83) | 0.2036 | 19.83 (2.62, 149.49) | 0.0038 | 17.27 (2.04, 144.18) | 0.0085 |
|  Post-intervention trend difference, treated (β7) | 0.93 (0.90, 0.96) | <0.0001 | 0.94 (0.90, 0.97) | 0.0002 | 0.95 (0.91, 0.99) | 0.0173 | 0.95 (0.92, 0.98) | 0.0040 | 0.96 (0.93, 1.00) | 0.0679 | 0.97 (0.94, 0.99) | 0.0056 |
|  Per 100 booth-hours | 0.32 (0.18, 0.57) | <0.0001 | 0.38 (0.20, 0.74) | 0.0046 | 0.60 (0.28, 1.28) | 0.1835 | 0.62 (0.27, 1.24) | 0.2613 | 0.38 (0.20, 0.73) | 0.0040 | 0.40 (0.19, 0.83) | 0.0140 |
|  Per 100 OAT recipients | 1.31 (0.86, 1.99) | 0.2053 | 1.27 (0.70, 2.29) | 0.4303 | 0.83 (0.62, 1.11) | 0.2015 | 0.83 (0.73, 0.95) | 0.0058 | 0.65 (0.43, 0.97) | 0.0342 | 0.64 (0.46, 0.89) | 0.0087 |
|  Per 100 naloxone kits dispensed | 1.24 (1.08, 1.42) | 0.0018 | 1.20 (1.04, 1.40) | 0.0155 | 1.05 (0.86, 1.28) | 0.6383 | 1.05 (0.89, 1.23) | 0.5681 | 1.14 (0.95, 1.35) | 0.1619 | 1.14 (0.92, 1.41) | 0.2294 |
| Ottawa |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.02 (1.01, 1.03) | <0.0001 | 1.02 (1.01, 1.03) | <0.0001 | 1.01 (1.00, 1.02) | 0.2158 | 1.01 (1.00, 1.01) | 0.0005 | 1.01 (1.00, 1.03) | 0.0724 | 1.02 (1.00, 1.03) | 0.0260 |
|  Pre-intervention level difference, treated (β2) | 0.84 (0.42, 1.69) | 0.6350 | 0.91 (0.41, 1.98) | 0.8024 | 1.05 (0.80, 1.39) | 0.7366 | 1.08 (0.87, 1.34) | 0.5055 | 1.06 (0.68, 1.66) | 0.8116 | 1.08 (0.58, 2.00) | 0.8107 |
|  Pre-intervention trend difference, treated (β3) | 1.00 (0.98, 1.03) | 0.7495 | 1.00 (0.97, 1.03) | 0.8299 | 1.00 (0.98, 1.01) | 0.6302 | 1.00 (0.98, 1.01) | 0.7199 | 1.00 (0.98, 1.03) | 0.7541 | 1.00 (0.98, 1.03) | 0.7433 |
|  Post-intervention level difference, synthetic control (β4) | 1.23 (1.00, 1.53) | 0.0533 | 1.26 (1.02, 1.56) | 0.0356 | 0.97 (0.75, 1.25) | 0.7905 | 0.97 (0.80, 1.16) | 0.7063 | 1.00 (0.66, 1.51) | 0.9997 | 0.99 (0.64, 1.52) | 0.9574 |
|  Post-intervention trend difference, synthetic control (β5) | 0.98 (0.97, 0.99) | 0.0022 | 0.98 (0.97, 1.00) | 0.0395 | 0.99 (0.97, 1.00) | 0.0257 | 0.99 (0.98, 0.99) | <0.0001 | 1.00 (0.98, 1.02) | 0.9573 | 1.00 (0.98, 1.02) | 0.9249 |
|  Post-intervention level difference, treated (β6) | 1.05 (0.72, 1.53) | 0.8054 | 1.01 (0.71, 1.44) | 0.9566 | 0.78 (0.50, 1.20) | 0.2549 | 0.76 (0.52, 1.08) | 0.1367 | 1.70 (0.91, 3.16) | 0.0975 | 1.64 (0.80, 3.37) | 0.1734 |
|  Post-intervention trend difference, treated (β7) | 1.00 (0.98, 1.03) | 0.7053 | 1.01 (0.98, 1.04) | 0.5968 | 1.00 (0.98, 1.02) | 0.9844 | 1.00 (0.98, 1.02) | 0.8725 | 1.00 (0.98, 1.03) | 0.7770 | 1.01 (0.97, 1.04) | 0.7301 |
|  Per 100 booth-hours | 0.95 (0.92, 0.97) | <0.0001 | 0.95 (0.92, 0.99) | 0.0091 | 0.98 (0.96, 1.02) | 0.2974 | 0.99 (0.95, 1.03) | 0.5601 | 0.94 (0.91, 0.98) | 0.0011 | 0.95 (0.90, 1.00) | 0.0504 |
|  Per 100 OAT recipients | 0.62 (0.06, 6.88) | 0.6981 | 0.74 (0.04, 13.96) | 0.8379 | 1.23 (1.02, 1.50) | 0.0342 | 1.26 (1.12, 1.42) | 0.0002 | 1.08 (0.83, 1.42) | 0.5616 | 1.09 (0.73, 1.63) | 0.6570 |
|  Per 100 naloxone kits dispensed | 1.14 (1.03, 1.24) | 0.0073 | 1.09 (0.95, 1.25) | 0.2224 | 1.17 (1.02, 1.33) | 0.0170 | 1.13 (1.01, 1.28) | 0.0387 | 0.98 (0.83, 1.15) | 0.7772 | 0.94 (0.78, 1.15) | 0.5593 |
| Thunder Bay |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.03 (1.01, 1.04) | <0.0001 | 1.03 (1.02, 1.04) | <0.0001 | 1.00 (0.98, 1.02) | 0.7122 | 0.99 (0.97, 1.01) | 0.3748 | 1.04 (1.02, 1.07) | 0.0018 | 1.05 (1.02, 1.07) | 0.0002 |
|  Pre-intervention level difference, treated (β2) | 1.15 (0.21, 6.46) | 0.8731 | 1.39 (0.39, 4.98) | 0.6113 | 0.65 (0.07, 6.02) | 0.7046 | 0.48 (0.08, 2.95) | 0.4293 | 3.49 (0.51, 23.82) | 0.1527 | 4.62 (0.83, 25.67) | 0.0804 |
|  Pre-intervention trend difference, treated (β3) | 1.01 (0.99, 1.03) | 0.3785 | 1.01 (0.99, 1.03) | 0.2090 | 1.00 (0.98, 1.02) | 0.9990 | 1.00 (0.98, 1.02) | 0.8362 | 1.01 (0.99, 1.04) | 0.3149 | 1.02 (0.99, 1.04) | 0.1785 |
|  Post-intervention level difference, synthetic control (β4) | 0.97 (0.68, 1.37) | 0.8475 | 1.00 (0.77, 1.29) | 0.9889 | 0.81 (0.51, 1.28) | 0.3599 | 0.84 (0.49, 1.43) | 0.5221 | 1.01 (0.58, 1.72) | 0.9770 | 1.00 (0.56, 1.79) | 0.9913 |
|  Post-intervention trend difference, synthetic control (β5) | 1.00 (0.98, 1.02) | 0.7765 | 1.00 (0.98, 1.01) | 0.8328 | 0.99 (0.96, 1.02) | 0.5364 | 0.99 (0.97, 1.01) | 0.3838 | 0.99 (0.96, 1.02) | 0.5628 | 0.99 (0.96, 1.02) | 0.5597 |
|  Post-intervention level difference, treated (β6) | 0.81 (0.40, 1.64) | 0.5543 | 0.95 (0.56, 1.61) | 0.8489 | 0.49 (0.14, 1.75) | 0.2740 | 0.46 (0.23, 0.92) | 0.0282 | 1.60 (0.62, 4.22) | 0.3131 | 1.78 (0.76, 4.19) | 0.1839 |
|  Post-intervention trend difference, treated (β7) | 0.98 (0.94, 1.01) | 0.1302 | 0.98 (0.96, 1.00) | 0.1101 | 0.97 (0.93, 1.02) | 0.2912 | 0.97 (0.93, 1.01) | 0.1414 | 1.02 (0.98, 1.07) | 0.4797 | 1.03 (0.98, 1.08) | 0.2045 |
|  Per 100 booth-hours | 0.98 (0.84, 1.15) | 0.8095 | 0.93 (0.84, 1.03) | 0.1729 | 1.16 (0.87, 1.55) | 0.2988 | 1.19 (1.01, 1.39) | 0.0335 | 0.77 (0.64, 0.94) | 0.0075 | 0.75 (0.64, 0.88) | 0.0004 |
|  Per 100 OAT recipients | 1.03 (0.87, 1.22) | 0.7656 | 1.01 (0.89, 1.14) | 0.8847 | 1.05 (0.84, 1.31) | 0.6519 | 1.08 (0.89, 1.31) | 0.4216 | 0.94 (0.76, 1.17) | 0.4708 | 0.92 (0.76, 1.11) | 0.3739 |
|  Per 100 naloxone kits dispensed | 1.06 (0.97, 1.16) | 0.2109 | 1.02 (0.93, 1.13) | 0.6717 | 1.14 (0.97, 1.34) | 0.1215 | 1.17 (1.00, 1.38) | 0.0567 | 0.89 (0.78, 1.04) | 0.1337 | 0.87 (0.78, 0.97) | 0.0104 |
| Guelph |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.02 (1.01, 1.03) | 0.0002 | 1.02 (1.01, 1.04) | 0.0019 | 1.01 (0.99, 1.04) | 0.3136 | 1.01 (1.00, 1.03) | 0.0315 | 1.01 (0.96, 1.06) | 0.7901 | 1.01 (0.98, 1.04) | 0.3644 |
|  Pre-intervention level difference, treated (β2) | 1.02 (0.70, 1.50) | 0.9050 | 1.05 (0.72, 1.52) | 0.8129 | 0.77 (0.25, 2.33) | 0.6405 | 0.73 (0.43, 1.21) | 0.2210 | 2.25 (0.27, 18.40) | 0.4509 | 1.83 (0.58, 5.80) | 0.3024 |
|  Pre-intervention trend difference, treated (β3) | 1.00 (0.98, 1.02) | 0.9717 | 1.00 (0.98, 1.01) | 0.9672 | 1.00 (0.97, 1.02) | 0.7617 | 0.99 (0.98, 1.01) | 0.4814 | 1.02 (0.96, 1.08) | 0.5074 | 1.01 (0.98, 1.05) | 0.4023 |
|  Post-intervention level difference, synthetic control (β4) | 1.03 (0.65, 1.63) | 0.9031 | 0.98 (0.69, 1.40) | 0.9154 | 0.87 (0.56, 1.35) | 0.5276 | 0.87 (0.69, 1.09) | 0.2149 | 1.09 (0.51, 2.32) | 0.8199 | 1.07 (0.56, 2.03) | 0.8319 |
|  Post-intervention trend difference, synthetic control (β5) | 0.98 (0.97, 1.00) | 0.0112 | 0.98 (0.97, 1.00) | 0.0252 | 0.99 (0.96, 1.02) | 0.5100 | 0.99 (0.98, 1.00) | 0.0755 | 1.01 (0.96, 1.07) | 0.6775 | 1.01 (0.97, 1.04) | 0.6926 |
|  Post-intervention level difference, treated (β6) | 0.81 (0.44, 1.50) | 0.5043 | 0.89 (0.50, 1.57) | 0.6884 | 0.99 (0.42, 2.33) | 0.9812 | 1.07 (0.54, 2.13) | 0.8428 | 0.93 (0.25, 3.54) | 0.9159 | 1.04 (0.36, 3.05) | 0.9411 |
|  Post-intervention trend difference, treated (β7) | 0.97 (0.94, 1.00) | 0.0711 | 0.97 (0.93, 1.00) | 0.0516 | 0.99 (0.94, 1.05) | 0.8063 | 0.99 (0.94, 1.05) | 0.7565 | 0.93 (0.85, 1.02) | 0.1060 | 0.94 (0.88, 1.00) | 0.0963 |
|  Per 100 booth-hours | 1.51 (1.15, 2.00) | 0.0035 | 1.45 (1.12, 1.86) | 0.0042 | 1.26 (0.77, 2.06) | 0.3531 | 1.21 (0.83, 1.76) | 0.3165 | 1.44 (0.73, 2.85) | 0.2898 | 1.29 (0.82, 2.03) | 0.2737 |
|  Per 100 OAT recipients | 1.01 (0.69, 1.48) | 0.9692 | 1.04 (0.88, 1.23) | 0.6435 | 0.88 (0.51, 1.53) | 0.6555 | 0.86 (0.68, 1.09) | 0.2022 | 1.61 (0.57, 4.58) | 0.3721 | 1.45 (0.84, 2.50) | 0.1861 |
|  Per 100 naloxone kits dispensed | 1.04 (0.89, 1.21) | 0.6069 | 1.06 (0.89, 1.27) | 0.5009 | 0.93 (0.72, 1.19) | 0.5468 | 0.96 (0.72, 1.27) | 0.7552 | 1.02 (0.75, 1.39) | 0.8939 | 0.98 (0.72, 1.32) | 0.8796 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Emergency department visits  | Hospitalizations  | Deaths |  |
|  | Crude (95% CI) | P-value | Adj.\* (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value | Crude (95% CI) | P-value | Adj. (95% CI) | P-value |
| Waterloo |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.00 (0.98, 1.02) | 0.8125 | 1.01 (0.98, 1.04) | 0.4537 | 0.99 (0.97, 1.01) | 0.2832 | 0.99 (0.98, 1.01) | 0.4469 | 1.01 (0.99, 1.04) | 0.3032 | 1.02 (0.99, 1.05) | 0.1910 |
|  Pre-intervention level difference, treated (β2) | 1.87 (0.76, 4.64) | 0.1747 | 1.27 (0.38, 4.26) | 0.6952 | 0.84 (0.45, 1.56) | 0.5712 | 0.80 (0.57, 1.12) | 0.1932 | 0.90 (0.57, 1.41) | 0.6398 | 0.96 (0.55, 1.69) | 0.8917 |
|  Pre-intervention trend difference, treated (β3) | 1.00 (0.99, 1.02) | 0.5924 | 1.00 (0.98, 1.02) | 0.8925 | 0.99 (0.98, 1.01) | 0.2810 | 0.99 (0.98, 1.00) | 0.1530 | 0.98 (0.96, 1.01) | 0.1484 | 0.98 (0.96, 1.01) | 0.1353 |
|  Post-intervention level difference, synthetic control (β4) | 0.89 (0.67, 1.19) | 0.4242 | 0.79 (0.61, 1.01) | 0.0617 | 0.64 (0.41, 1.01) | 0.0535 | 0.60 (0.52, 0.70) | <0.0001 | 0.74 (0.43, 1.30) | 0.2959 | 0.65 (0.41, 1.05) | 0.0800 |
|  Post-intervention trend difference, synthetic control (β5) | 1.04 (1.01, 1.08) | 0.0047 | 1.04 (1.01, 1.07) | 0.0019 | 1.07 (1.02, 1.11) | 0.0040 | 1.07 (1.05, 1.08) | <0.0001 | 1.03 (0.97, 1.10) | 0.3144 | 1.04 (0.99, 1.09) | 0.1498 |
|  Post-intervention level difference, treated (β6) | 0.89 (0.58, 1.37) | 0.5946 | 0.94 (0.59, 1.49) | 0.8023 | 2.53 (1.34, 4.80) | 0.0044 | 2.63 (1.75, 3.96) | <0.0001 | 0.93 (0.43, 2.01) | 0.8493 | 0.96 (0.52, 1.75) | 0.8840 |
|  Post-intervention trend difference, treated (β7) | 0.96 (0.91, 1.01) | 0.1156 | 0.96 (0.91, 1.02) | 0.1684 | 0.96 (0.89, 1.03) | 0.2891 | 0.96 (0.90, 1.03) | 0.3110 | 1.03 0.93, 1.14) | 0.5234 | 1.04 (0.96, 1.12) | 0.3281 |
|  Per 100 booth-hours | 1.06 (0.83, 1.35) | 0.6343 | 1.05 (0.87, 1.27) | 0.6351 | 0.84 (0.60, 1.18) | 0.3137 | 0.81 (0.56, 1.18) | 0.2776 | 1.09 (0.77, 1.54) | 0.6210 | 1.07 (0.86, 1.32) | 0.5619 |
|  Per 100 OAT recipients | 1.27 (0.87, 1.87) | 0.2143 | 1.11 (0.68, 1.81) | 0.6782 | 1.11 (0.75, 1.65) | 0.6093 | 1.04 (0.84, 1.30) | 0.6914 | 1.12 (0.78, 1.60) | 0.5494 | 1.10 (0.75, 1.62) | 0.6274 |
|  Per 100 naloxone kits dispensed | 1.21 (1.05, 1.40) | 0.0076 | 1.11 (0.94, 1.30) | 0.2229 | 1.16 (0.92, 1.46) | 0.2015 | 1.11 (0.91, 1.35) | 0.3221 | 1.08 (0.81, 1.45) | 0.6105 | 0.95 (0.61, 1.47) | 0.8043 |
| Aggregate |  |  |  |  |  |  |  |  |  |  |  |  |
|  Pre-intervention trend, synthetic control (β1) | 1.03 (1.02, 1.04) | <0.0001 | 1.03 (1.02, 1.04) | <0.0001 | 1.01 (1.00, 1.02) | 0.1133 | 1.01 (1.00, 1.01) | 0.0245 | 1.03 (1.02, 1.04) | <0.0001 | 1.03 (1.02, 1.04) | <0.0001 |
|  Pre-intervention level difference, treated (β2) | 1.36 (1.23, 1.49) | <0.0001 | 1.36 (1.17, 1.58) | <0.0001 | 1.49 (0.80, 2.79) | 0.2070 | 1.49 (0.96, 2.31) | 0.0721 | 2.14 (1.52, 3.03) | <0.0001 | 2.14 (1.49, 3.09) | <0.0001 |
|  Pre-intervention trend difference, treated (β3) | 1.01 (1.00, 1.01) | 0.0037 | 1.01 (1.00, 1.01) | 0.0420 | 1.00 (1.00, 1.01) | 0.6848 | 1.00 (1.00, 1.01) | 0.5266 | 1.01 (1.00, 1.02) | 0.0089 | 1.01 (1.00, 1.02) | 0.0064 |
|  Post-intervention level difference, synthetic control (β4) | 1.07 (0.96, 1.19) | 0.2070 | 1.07 (1.00, 1.15) | 0.0550 | 0.88 (0.74, 1.04) | 0.1414 | 0.88 (0.76, 1.01) | 0.0700 | 0.95 (0.78, 1.15) | 0.5912 | 0.95 (0.84, 1.07) | 0.3815 |
|  Post-intervention trend difference, synthetic control (β5) | 0.98 (0.97, 0.99) | 0.0011 | 0.98 (0.97, 0.99) | <0.0001 | 1.00 (0.98, 1.02) | 0.7380 | 1.00 (0.98, 1.01) | 0.6352 | 1.00 (0.98, 1.02) | 0.9995 | 1.00 (0.99, 1.01) | 0.9989 |
|  Post-intervention level difference, treated (β6) | 0.71 (0.57, 0.90) | 0.0040 | 0.71 (0.60, 0.84) | <0.0001 | 0.99 (0.67, 1.46) | 0.9597 | 0.99 (0.74, 1.33) | 0.9473 | 1.15 (0.76, 1.74) | 0.5062 | 1.15 (0.96, 1.38) | 0.1255 |
|  Post-intervention trend difference, treated (β7) | 0.96 (0.93, 0.99) | 0.0038 | 0.96 (0.92, 0.99) | 0.0261 | 0.95 (0.91, 1.00) | 0.0534 | 0.95 (0.92, 0.98) | 0.0014 | 1.00 (0.95, 1.05) | 0.9541 | 1.00 (0.96, 1.04) | 0.9432 |
|  Per 100 booth-hours | 5.29 (1.26, 22.10) | 0.0225 | 5.29 (1.03, 27.24) | 0.0466 | 2.63 (0.25, 28.17) | 0.4240 | 2.63 (0.57, 12.07) | 0.2133 | 0.37 (0.03, 4.89) | 0.4537 | 0.37 (0.09, 1.60) | 0.1847 |
|  Per 100 OAT recipients | 0.04 (0.00, 8.97) | 0.2484 | 0.04 (0.00, 23.39) | 0.3278 | 0.08 (0.00, 191.72) | 0.5232 | 0.08 (0.00, 23.37) | 0.3818 | 0.00 (0.00, 0.47) | 0.0346 | 0.00 (0.00, 0.15) | 0.0162 |
|  Per 100 naloxone kits dispensed | 1.73 (0.15, 20.31) | 0.6625 | 1.73 (0.07, 40.03) | 0.7322 | 4.51 (0.08, 249.64) | 0.4619 | 4.51 (0.49, 41.28) | 0.1822 | 0.01 (0.00, 1.06) | 0.0531 | 0.01 (0.00, 1.05) | 0.0528 |

\*Adjusted for seasonality using harmonic terms and with robust standard errors generated using Newey-West method, except for aggregate analysis which does not adjust for seasonality given multiple baseline approach.





Figure 1. Controlled interrupted time-series of opioid-related ED visits plotted per treated public health unit – synthetic control pair, with counterfactual; Dark vertical dashed line = March 2020





Figure 2. Controlled interrupted time-series of hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020







Figure 3. Controlled interrupted time-series of mortalities plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020